Description
The CliniMACS Prodigy automates cell manufacturing workflows from cell separation, cultivation and genetic engineering, to final product formulation, ensuring GMP-compliant, reproducible results. Its closed-system design enhances safety, reduces cleanroom requirements, and minimizes hands-on time. With flexible, customizable protocols, the CliniMACS Prodigy supports many cell types and manufacturing models, empowering centralized and point-of-care production. By automating complex processes, the CliniMACS Prodigy advances the development of cell-based therapies for cancer, autoimmune, and neurodegenerative diseases, accelerating the path to precision medicine.
Reliable standardization
The CliniMACS Prodigy ensures automated and standardized processes, minimizing manual intervention and reducing variability. This leads to consistent, reproducible results, which are essential for high-quality cell and gene therapy manufacturing.
Enhanced safety and compliance
With its closed tubing system, the platform significantly reduces the need for extensive cleanroom facilities, simplifying compliance with regulatory standards. This closed design enhances both product sterility and operator safety, lowering contamination risks.
Exceptional versatility
The CliniMACS Prodigy supports diverse cell manufacturing processes, including T cells, NK cells, stem cells, and other specialized cell types. Its standard and customizable software protocols ensure seamless adaptation to various therapy approaches.
Seamless scalability
Designed for both centralized and decentralized manufacturing, the platform facilitates easy scale-out and protocol transfer. This capability enables smooth transition from clinical development to commercial-scale production.